SGLT-2 inhibitors reduce dialysis risk: landmark study

Australian-led review finds the gliflozins reduce risk of death by 33%

SGLT-2 inhibitors reduce the risk of kidney dialysis, transplantation and death from kidney disease by one-third, a landmark Australian-led review has found.